candesartan has been researched along with Bladder Cancer in 3 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In this study, we evaluated the efficacy of the AT1R antagonist candesartan in bladder cancer." | 7.73 | Angiotensin II type 1 receptor antagonist candesartan as an angiogenic inhibitor in a xenograft model of bladder cancer. ( Horiguchi, Y; Kikuchi, E; Kosugi, M; Miyajima, A; Murai, M, 2006) |
| "To examine whether candesartan enhances the cytotoxicity of cis-dichlorodiammineplatinum (CDDP) in mice with bladder cancer as a method to enhance the therapeutic effects of CDDP." | 3.75 | Angiotensin II type 1 receptor antagonist enhances cis-dichlorodiammineplatinum-induced cytotoxicity in mouse xenograft model of bladder cancer. ( Horiguchi, Y; Kikuchi, E; Kosaka, T; Kosugi, M; Miyajima, A; Murai, M; Oya, M, 2009) |
| " In this study, we evaluated the efficacy of the AT1R antagonist candesartan against bladder cancer." | 3.74 | Effect of angiotensin II type 1 receptor antagonist on tumor growth and angiogenesis in a xenograft model of human bladder cancer. ( Horiguchi, Y; Kikuchi, E; Kosaka, T; Kosugi, M; Miyajima, A; Murai, M, 2007) |
| " In this study, we evaluated the efficacy of the AT1R antagonist candesartan in bladder cancer." | 3.73 | Angiotensin II type 1 receptor antagonist candesartan as an angiogenic inhibitor in a xenograft model of bladder cancer. ( Horiguchi, Y; Kikuchi, E; Kosugi, M; Miyajima, A; Murai, M, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kosugi, M | 3 |
| Miyajima, A | 3 |
| Kikuchi, E | 3 |
| Kosaka, T | 2 |
| Horiguchi, Y | 3 |
| Murai, M | 3 |
| Oya, M | 1 |
3 other studies available for candesartan and Bladder Cancer
| Article | Year |
|---|---|
Angiotensin II type 1 receptor antagonist enhances cis-dichlorodiammineplatinum-induced cytotoxicity in mouse xenograft model of bladder cancer.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antineoplastic Agents; Benzimidazoles; Biphenyl Co | 2009 |
Angiotensin II type 1 receptor antagonist candesartan as an angiogenic inhibitor in a xenograft model of bladder cancer.
Topics: Aged; Angiogenesis Inhibitors; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Bip | 2006 |
Effect of angiotensin II type 1 receptor antagonist on tumor growth and angiogenesis in a xenograft model of human bladder cancer.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Benz | 2007 |